Recent Biotech, Cannabis, Food & Drug, & Pharma Administration News

Publication Date Organization
Nov
22
2024
 EPA Releases Updates to Suggested Pesticide Benefits Information Submittals Bergeson & Campbell, P.C.
Nov
22
2024
 McDermott+ Check-Up: November 22, 2024 McDermott Will & Emery
Nov
22
2024
 Gaetz Out as Possible Attorney General, Pam Bondi New Nominee: A Discussion Still Limited to Cannabis Implications Bradley Arant Boult Cummings LLP
Nov
22
2024
 PBM Policy and Legislative Update — Fall 2024 Mintz
Nov
22
2024
 CLP Amendment and Updated CLP Guidance Published (Highly Relevant to Endocrine Disruptors) Keller and Heckman LLP
Nov
22
2024
 Owner, Operator of Texas Lab Charged for $79 Million Medical Testing Fraud Scheme ArentFox Schiff LLP
Nov
21
2024
 October 2024 Bounty Hunter Plaintiff Claims Keller and Heckman LLP
Nov
21
2024
 Raising Capital in the Cannabis Business: Pitfalls and Possibilities Bradley Arant Boult Cummings LLP
Nov
21
2024
 The 2025 Final Hospital Outpatient Prospective Payment System and Physician Fee Schedule Rules: What Pharma Stakeholders Need to Know ArentFox Schiff LLP
Nov
20
2024
 Biomanufacturing Interagency Working Group Identifies Actions to Increase U.S. Biomanufacturing Capacity Bergeson & Campbell, P.C.
Nov
20
2024
 California Department of Public Health Rejects Petition Requesting Synthetic Dye Warnings Keller and Heckman LLP
Nov
20
2024
 Matt Gaetz Nominated as Attorney General: A Discussion Limited to Cannabis Implications Bradley Arant Boult Cummings LLP
Nov
20
2024
 FDA Clinical Investigations: New Guidance on Electronic Systems Foley & Lardner LLP
Nov
20
2024
 California Ballot Proposition 34 Targets Spending by Certain 340B Covered Entities McDermott Will & Emery
Nov
19
2024
 PA Department of Revenue Not Ready to Double Tax Ready to Drink Cocktails Norris McLaughlin P.A.
Nov
19
2024
 Unpacking Johnson & Johnson’s Lawsuit Over 340B Rebate Model Mintz
Nov
19
2024
 FDA Requests Information on PFAS in Seafood Keller and Heckman LLP
Nov
19
2024
 Trending in Telehealth: October 29 – November 11, 2024 McDermott Will & Emery
Nov
18
2024
 Still in Telemedicine Limbo: DEA Issues Third Temporary Rule Extending Controlled Substance Prescribing Flexibilities Through December 2025 Polsinelli PC
Nov
18
2024
 DEA Extends Telehealth Lifeline for Patients Robinson & Cole LLP
Nov
18
2024
 DEA Issues Third Extension to Public Health Emergency Telemedicine Prescribing Flexibilities, Through 2025 Epstein Becker & Green, P.C.
Nov
18
2024
 AAFCO Seeks Public Feedback on Proposed New Additions to the Common Food Index Keller and Heckman LLP
Nov
18
2024
 New DEA Rule Extends Controlled Substance Telemedicine Prescribing Flexibilities One More Year Foley & Lardner LLP
Nov
18
2024
 DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025 McDermott Will & Emery
Nov
18
2024
 DEA Extends COVID-19 Telemedicine Prescribing Flexibilities a Third Time Robinson & Cole LLP
Nov
18
2024
 Pair of First Circuit Cases Give Court Opportunities for Recognizing Scope of Federal Authority to Regulate Marijuana Businesses Bradley Arant Boult Cummings LLP
Nov
18
2024
 As the (Customs and Trade) World Turns: November 2024 ArentFox Schiff LLP
Nov
15
2024
 Recent Federal Developments for November, 2024 Bergeson & Campbell, P.C.
Displaying 1 - 28 of 11741
Subscribe to The 10 Latest Biological, Life Sciences, and Cleantech Law Articles
 
NLR Logo
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins